Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluDReSS: Fludrocortisone dosing in septic shock
NCT04494789Phase 2Completed
- Sponsor
- The George Institute for Global Health
- Start
- Feb 2021
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fludrocortisone in septic shock (4 arms), sponsored by The George Institute for Global Health. Primary endpoints: Time to resolution of shock at 7 days and Vasopressor Responsiveness at 7 days. Started Feb 2021; status: completed.
02
Drugs
fludrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04494789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494789.